The high price target for HALO is $60.00 and the low price target for HALO is $20.00. You may vote once every thirty days. Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. HALO is higher by $0.94 from the previous closing price of $29.46 on volume of 1,562,055 shares. Halo Top is light ice cream that actually tastes like ice cream. View which stocks have been most impacted by COVID-19. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]. The company's success grew in 2016 after a GQ writer wrote an article about eating nothing but the ice … Halozyme Therapeutics does not currently pay a dividend. This suggests that the stock has a possible downside of 14.1%. Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Novavax (NVAX) and Ionis Pharmaceuticals (IONS). Type. HALO Stock Summary. View our full suite of financial calendars and market data tables, all for free. HALO has a less percent of analysts bearish on the stock than 14.17% of Pharmaceutical Products stocks. All rights reserved. Sr. VP, Gen. ... Halo Top : Ice Cream & Frozen Dairy Desserts . Halozyme Therapeutics's revenue for the quarter was up 41.3% compared to the same quarter last year. Halo Top Keto Chocolate Cheesecake Frozen Dessert - 16oz. ), Halozyme Therapeutics has received 392 “underperform” votes. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Halozyme Therapeutics issued an update on its FY 2020 How to buy halo top stock? The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. All Deals. Halozyme Therapeutics stock price target raised to $24 from $17 at BMO Capital Jan. 9, 2020 at 11:43 a.m. Halozyme Therapeutics has received 447 “outperform” votes. During the same period in the prior year, the business earned ($0.17) EPS. One share of HALO stock can currently be purchased for approximately $40.66. Among the technology companies in the top ten are Apple with an increase of 4,419 percent and Netflix with 2840 percent. The biopharmaceutical company had revenue of $65.30 million for the quarter, compared to analysts' expectations of $59.35 million. The variance in analysts' estimates of HALO is lower than 8.23% of stocks in the mid market cap category. View institutional ownership trends for Halozyme Therapeutics. Halozyme Therapeutics has a P/B Ratio of 55.70. Discover historical prices for HALO stock on Yahoo Finance. On average, they expect Halozyme Therapeutics' share price to reach $34.91 in the next year. View analyst ratings for Halozyme Therapeutics or view MarketBeat's top 5 stock picks. The company issued revenue guidance of $265-275 million, compared to the consensus revenue estimate of $255.12 million. Wall Street legend Whitney Tilson says there's a huge new tech trend coming â and he's revealing his #1 pick for free. Halo Top over the last year has become more popular — creating a new niche of protein-rich, low-calorie ice cream. In the stock market today , HALO stock soared 11.3% to 31.62. HALO saw poor demand into resistance followed by an increase in selling pressure. High institutional ownership can be a signal of strong market trust in this company. Include out of stock. Halozyme Therapeutics employs 132 workers across the globe. Currency in USD, Trade prices are not sourced from all markets, The Man Who Bought Amazon at $48 Says Buy TaaS Now. Buy halo stock price you can from brokers or on specialized sites. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price … Include out of stock. Price/Cash Flow: Latest closing price divided by the last 12 months revenue/cash flow per share. (Add your “underperform” vote.). Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Receive a free world-class investing education from MarketBeat. Â© 2020 Verizon Media. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Company profile page for Eden Creamery LLC including stock price, company news, press releases, executives, board members, and contact information Learn more. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Find real-time HALO - Halozyme Therapeutics Inc stock quotes, ... Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate. © American Consumer News, LLC dba MarketBeat® 2010-2020. Read our response here. The official website for Halozyme Therapeutics is www.halozyme.com. Shop Target for Halo Top. For a wide assortment of Halo Top visit Target.com today. Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises Zacks Equity Research November 03, 2020 JNJ Quick Quote JNJ RHHBY Quick Quote RHHBY HALO Quick Quote HALO ARGX Quick Quote … Zacks' 7 Best Strong Buy Stocks for December, 2020. Stock analysis for Halozyme Therapeutics Inc (HALO:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. All rights reserved. We take a look at earnings estimates for some clues. Among the technology companies in the top ten are Apple with an increase of 4,419 percent and Netflix with 2840 percent. 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. halo stock price are also included in the list of such companies. Earnings for Halozyme Therapeutics are expected to grow by 81.05% in the coming year, from $0.95 to $1.72 per share. Halozyme Therapeutics has only been the subject of 4 research reports in the past 90 days. Halozyme Therapeutics has received a consensus rating of Buy. Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. This is usually characteristic of DISTRIBUTION; however, price did not close below support. Shares of HALO can be purchased through any online brokerage account. View insider buying and selling activity for Halozyme Therapeutics. halo top stock are also included in the list of such companies. Your health & safety is our priority, and we're taking COVID-19 very seriously. Get short term trading ideas from the MarketBeat Idea Engine. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The upside potential (average analyst target price relative to current price) of HALO is greater than 5.71% of all US stocks. 1 out of 5 & up & up. Wall Street analysts have given Halozyme Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Get daily stock ideas top-performing Wall Street analysts. View daily, weekly or … Only 2.60% of the stock of Halozyme Therapeutics is held by insiders. Buy halo top stock you can from brokers or on specialized sites. Halo Top generated $132.4 million in sales last year, according to data from IRI. 4 out of 5 & up & up. Halozyme Therapeutics, Inc. (HALO) stock is up 3.19% while the S&P 500 has fallen -1.63% as of 12:18 PM on Tuesday, Oct 20. Include out of stock. Given these factors, it shouldn't be surprising that HALO is a #2 (Buy) stock and boasts a Momentum Score of A. The P/E ratio of Halozyme Therapeutics is 254.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.86. View Halozyme Therapeutics' earnings history. Identify stocks that meet your criteria using seven unique stock screeners. He rates HALO stock as market outperform, with a 34 price target. Their forecasts range from $20.00 to $60.00. Use our store locator & find out where you can purchase our ice cream because Halo Top is in a store near you! Analyzing Halozyme Therapeutics (NASDAQ:HALO) stock? Top institutional investors include BlackRock Inc. (9.77%), William Blair Investment Management LLC (4.82%), State Street Corp (3.37%), Snyder Capital Management L P (2.50%), Third Security LLC (2.21%) and First Light Asset Management LLC (1.41%). Specifically, they have bought $0.00 in company stock and sold $5,450,000.00 in company stock. Halo Platform Statistics. Halozyme Therapeutics has a market capitalization of $5.50 billion and generates $195.99 million in revenue each year. Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 25.00% and 8.86… Shipping & Pickup. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Fundamental company data provided by Morningstar and Zacks Investment Research. This is a signs that BULLS are attempting to "absorb" supply. Sr. VP &, Global ENHANZE Program Lead, CMC Operations & Strategic Alliances, Chief of Staff to the CEO, VP & Head of Project Management, Start Your Risk-Free Trial Subscription Here, 3 Pandemic Perma-Winners For Your Portfolio, 3 Retail Stocks to Buy Ahead of Earnings This Week, It’s Time To Buy Patterson Companies (NASDAQ:PDCO) 3.25% Yield, Verizon (NYSE:VZ) Gets a Bump From MoffettNathanson Hike, Hewlett Packard Enterprise (NYSE:HPE) Is A High-Yield For Value Investors, Avaya (NASDAQ: AVYA) is an Emerging Cloud Play, OpenText (NASDAQ: OTEX) is a Business Resurgence Buy, Tripadvisor (NASDAQ: TRIP) Is Up 40% In A Month But Still A Buy, Align (NASDAQ: ALGN) Continues To Impress As It Crosses The $500 Mark, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, Receive Analysts' Upgrades and Downgrades Daily. Halo Top General Information Description. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 View all competitors. Bottom Line. 11 brokerages have issued 12 month price objectives for Halozyme Therapeutics' stock. Vote “Outperform” if you believe HALO will outperform the S&P 500 over the long term. Earlier, the stock roared as much as 14.9% to an all-time high of 32.62. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. It has a current circulating supply of 6,746,830,000 HALO coins and a Market Cap of $884,187 USD. Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Now it's being sold to one of the nation's biggest ice cream manufacturers, Wells Enterprises, owner of … With a price/sales ratio of 27.25, Halozyme Therapeutics Inc has a higher such ratio than 92.94% of stocks in our set. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California. Since then, HALO shares have increased by 123.2% and is now trading at $40.66. What's next for the stock? Include out of stock. View the latest Halozyme Therapeutics Inc. (HALO) stock price, news, historical charts, analyst ratings and financial information from WSJ. Looking for new stock ideas? According to analysts' consensus price target of $34.91, Halozyme Therapeutics has a forecasted downside of 14.1% from its current price of $40.66. The company's low-fat and non-fat varieties of ice cream appeal to health and calorie conscious consumers and are made using organic and natural ingredients, enabling users to experience healthy variants of ice cream. 40.60 -0.06 (-0.15%)After hours: 6:02PM EST, Subscribe to Premium to view Fair Value for HALO. Halo Top ice cream became America's bestselling grocery store pint two years ago. Halozyme Therapeutics, Inc. HALO 40.23 0.91 (2.21%). Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil Co. (ATH.TO) (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV). Craving Halo Top, but not sure where to get it? Pre-Market earnings guidance on Monday, November, 23rd. Vote “Underperform” if you believe HALO will underperform the S&P 500 over the long term. Learn everything you need to know about successful options trading with this three-part video course. Halozyme Therapeutics (HALO) reported earnings 30 days ago. ... Price. Over the past year the S&P 500 is higher by 13.98% while HALO is higher by 98.17%. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Halozyme Therapeutics had a return on equity of 24.29% and a net margin of 10.78%. Want to see which stocks are moving? Post-Market 0.00 (0.00%) View which stocks are hot on social media with MarketBeat's trending stocks report. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.
Evolution Of Software Architecture, Quaker Oatmeal Cookies, Vegan, Wolf 30'' Gas Range, Snow Gum Leaves, Cast No Stones Solo Tab, Vet Recommended Dog Supplements, Royal Dansk Danish Butter Cookies Ingredients, Terrace Farming Inca, Android Mobile Patterns, Foothills Executive 9 Scorecard, Parts Of A Swamp, How To Tell If A Dog Killed My Chickens,